Dog /

Breed profile · FDA CVM July 2026 extract

Shar Pei adverse-event record

Adverse-event filings for Shar Pei (Dog) in the FDA Center for Veterinary Medicine openFDA extract. Browse dog breeds, reactions, and outcomes below.

#97 of 510
by report volume (all breeds)
1,304
FDA CVM reports on file
7.5%
death-coded share of reports
#78 of 275
by death-coded share (≥50 reports)

How the 1,304 reports break down

By recorded gender -- every report on file for Shar Pei, no filtering.

Annual report volume

Annual adverse-event report trend Yearly FDA CVM adverse-event report counts for this breed. 87 65.25 43.5 21.75 0 2019 2020 2021 2022 2023 2024 2025 2026 Reports filed Death-coded reports
Annual report volume for Shar Pei drawn from FDA CVM filings.

Data updated September 2026

The verdict

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Shar Pei ranks #97 of 510 by total reports (1,304) and #78 of 275 by death-coded share (7.5%). National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).

93,675
Retriever - Labrador reports (#1)
99.0%
Atlantic Salmon (Salmo salar) death share (#1)
#97
This breed, reports of 510
#78
This breed, death share of 275

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Shar Pei has 1,304 reports now versus 1,280 in that prior snapshot: 24 more (1.9%).

Report change
+24
Death-coded reports
+3
Death-coded share
+0.1 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Shar Pei changes

Total Reports

1,304

High report volume

Deaths Reported

98

of 1,304 reports

Death-coded share of reports

7.5%

Above-median death-coded share

Avg Age at Report

5.5 yr

23.4 kg avg weight

Breed Safety Scorecard

F (30/100)

A weighted composite across 4 of 4 dimensions, each benchmarked against every tracked breed with at least 200 reports (n=185). Dimensions with insufficient data drop out and their weight redistributes to the rest, so a missing input never silently deflates the score.

Death rate F
7.5%

Share of reports coded as a fatality

Euthanasia rate F
3.1%

Share of reports resulting in euthanasia

Full recovery rate D
26.9%

Share of reports coded "Recovered/Normal"

5-year trend F
+24%

Change in annual report volume over the last 5 complete years

Death-Coded Outcome Share

Shar Pei death-coded reports 7.5%
Cross-breed median

7.5% of 1,304 shar pei reports involved a death outcome.

How to read this number

Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.

Where Shar Pei's death-coded share sits among indexed breeds

Death-coded share of FDA CVM reports, breeds with ≥50 reports (July 2026 extract)

8% 72nd percentile Higher share than 72% of 275 indexed breeds

5%–10%: 1 indexed breeds (0%). This entry sits in this band. 20%–25%: 2 indexed breeds (1%). Above this entry. 25%–30%: 3 indexed breeds (1%). Above this entry. 30%–35%: 4 indexed breeds (1%). Above this entry. 35%–40%: 5 indexed breeds (2%). Above this entry. 40%–45%: 6 indexed breeds (2%). Above this entry. 45%–50%: 3 indexed breeds (1%). Above this entry. 50%–55%: 7 indexed breeds (3%). Above this entry. 55%–60%: 7 indexed breeds (3%). Above this entry. 60%–65%: 21 indexed breeds (8%). Above this entry. 65%–70%: 11 indexed breeds (4%). Above this entry. 70%–75%: 15 indexed breeds (5%). Above this entry. 75%–80%: 13 indexed breeds (5%). Above this entry. 80%–85%: 11 indexed breeds (4%). Above this entry. 85%–90%: 12 indexed breeds (4%). Above this entry. 90%–95%: 12 indexed breeds (4%). Above this entry. 95%–100%: 142 indexed breeds (52%). Above this entry. Shar Pei 5% 100% every breed with ≥50 FDA reports, bucketed by value

Each bar is a band; taller bars hold more indexed breeds. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source FDA Center for Veterinary Medicine, openFDA adverse event extract (PlainBreed) · July 2026 extract

This histogram uses the same ≥50-report cohort as the highest death-coded share ranking. A higher share means more of this breed's reported events were death-coded, not a mortality rate for living animals.

Average weight at time of report: 23.4 kg (51.6 lbs)

Top Reported Reactions

Vomiting 227
Lethargy (see also Central nervous system depression in 'Neurological') 122
Diarrhoea 94
Emesis 90
Lack of efficacy - NOS 76
Lack of efficacy (endoparasite) - heartworm 76
Lack of efficacy (ectoparasite) - flea 65
Anorexia 62
INEFFECTIVE, HEARTWORM LARVAE 56
Seizure NOS 56
Death 48
Death by euthanasia 47
Other abnormal test result NOS 44
Not eating 38
Behavioural disorder NOS 33

Most Referenced Drugs

Milbemycin Oxime + Spinosad 219
Oclacitinib Maleate 130
Ivermectin + Pyrantel As Pamoate Salt 98
Afoxolaner 83
Spinosad 81
Moxidectin 67
Pyrantel Pamoate;Sarolaner 53
Carprofen 45
Bedinvetmab 41
Milbemycin Oxime + Praziquantel 39
Fluralaner Chew Tablets 31
Trilostane 25
Gabapentin 25
Maropitant Citrate 24
Fluralaner 13.64% 12-Week Chew 24

Outcome Breakdown

Outcome Unknown
395 (32.2%)
Recovered/Normal
351 (28.6%)
Ongoing
339 (27.6%)
Died
58 (4.7%)
Recovered with Sequela
45 (3.7%)
Euthanized
40 (3.3%)

Gender Distribution

Female 642 (49.2%)
Male 632 (48.5%)
Unknown 27 (2.1%)
Mixed 3 (0.2%)

Reports by Year

Year Reports Trend
2010 40
2011 62
2012 93
2013 102
2014 99
2015 79
2016 119
2017 100
2018 83
2019 87
2020 77
2021 59
2022 64
2023 62
2024 86
2025 73
2026 19

Shar Pei: high death-coded share in the FDA CVM extract

Signature read: 1,304 reports place Shar Pei in the upper third of breed filing volume (#97 of 510). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Shar Pei sits at #97 of 510 by report volume among all breeds and #81 of 298 among dog breeds, with 1,304 reports and 98 (7.5%) death-coded. On death-coded share among breeds with ≥50 reports, it ranks #78 of 275. Mean age at report: 5.5 years, average weight 23.4 kg (51.6 lbs).

Top reported signs: Vomiting (227), Lethargy (see also Central nervous system depression in 'Neurological') (122), Diarrhoea (94). Most-referenced drug: Milbemycin Oxime + Spinosad (219 reports), followed by Oclacitinib Maleate (130) and Ivermectin + Pyrantel As Pamoate Salt (98).

Outcome coding on 1,228 status-recorded reports is dominated by Outcome Unknown (32.2%). Annual submissions ranged 19-2,026 across 17 years on file.

Dog Breeds With a Similar Report Volume

Showing 6 of 297 dog breeds in our dataset, ranked by closest report volume.

Nationwide breeds with similar profiles

High-volume peer sets for Shar Pei drawn from openFDA outside the Dog family so the neighborhoods are not species containment (the similar-volume list above stays within species).

Similar death-coded share

Nearest other-species breeds with ≥50 reports (7.5% death-coded here).

Similar average weight

Nearest other-species breeds by reported average weight (23.4 kg here).

What to do with this dog

A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.

Frequently Asked Questions

How many FDA adverse event reports involve Shar Pei?
There are 1,304 adverse event reports involving Shar Pei in the FDA database, of which 98 were death-coded (7.5% of those reports). That is a share of REPORTED events, not a mortality rate for the breed: adverse events reach the FDA when something goes wrong, so the denominator is reports, never the population of animals. According to the same FDA CVM extract, Shar Pei ranks #97 of 510 by report volume among all breeds PlainBreed indexes (#81 of 298 among dog breeds).
Where does Shar Pei sit among other breeds in PlainBreed's corpus?
According to FDA CVM report volume, Shar Pei is #97 of 510 breeds indexed on PlainBreed (same ordering as the most-reported-breeds ranking). Inside Dog, it is #81 of 298. Among breeds with at least 50 reports, its death-coded share ranks #78 of 275 (same cohort as highest-death-rate). These are placement ranks in the reporting corpus, not clinical risk scores.
What are the most common adverse reactions reported for Shar Pei?
The most commonly reported adverse reactions for Shar Pei are Vomiting (227 reports), Lethargy (see also Central nervous system depression in 'Neurological') (122 reports), Diarrhoea (94 reports), Emesis (90 reports), Lack of efficacy - NOS (76 reports).
What drugs are most frequently associated with Shar Pei adverse events?
The drugs most frequently referenced in Shar Pei adverse event reports are Milbemycin Oxime + Spinosad (219 reports), Oclacitinib Maleate (130 reports), Ivermectin + Pyrantel As Pamoate Salt (98 reports), Afoxolaner (83 reports), Spinosad (81 reports).
What is the average age of Shar Pei in adverse event reports?
The average age of Shar Pei at the time of adverse event reports is 5.5 years, with an average weight of 23.4 kg (51.6 lbs).

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Shar Pei (Dog), extract as of July 2026 extract. 1,304 reports · 98 death-coded (7.5% of reports, not a mortality rate) · #97 of 510 by volume.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →